|
PUBLICATIONS (Ranked by Impact Factor of the Journal) |
LABORATORY RESEARCH
Androgen-Independent Molecular Imaging Vectors to Detect Castration-Resistant and Metastatic Prostate Cancer
Scientists evaluated the utility of prostate-specific enhancing sequence, an androgen-independent promoter in castration-resistant prostate cancer. [Cancer Res] Abstract | Press Release
Pax6 Represses Androgen Receptor-Mediated Transactivation by Inhibiting Recruitment of the Coactivator SPBP
In this study researchers have identified SPBP to act as a transcriptional coactivator of androgen receptor (AR). They also show that Pax6 inhibits SPBP-mediated enhancement of AR activity on the AR target gene probasin promoter, a repression that was partly reversed by increased expression of SPBP. [PLoS One] Abstract
Drug-Tolerant Cancer Cells Show Reduced Tumor-Initiating Capacity: Depletion of CD44+ Cells and Evidence for Epigenetic Mechanisms
Here, investigators chronically treated Du145 prostate cancer cells with etoposide, paclitaxel and some experimental drugs (i.e., staurosporine and 2 paclitaxel analogs), which led to populations of drug-tolerant cells. [PLoS One] Abstract
IL-18 Inhibits Growth of Murine Orthotopic Prostate Carcinomas via Both Adaptive and Innate Immune Mechanisms
In this study, the potential of interleukin (IL)-18 as an immunotherapy for prostate cancer was examined using the murine model of prostate carcinoma, RM1 and a bone metastatic variant RM1(BM)/B4H7-luc. [PLoS One] Abstract
Fibroblast Growth Factor and Ornithine Decarboxylase 5′-Untranslated Regions Enable Preferential Expression in Human Prostate Cancer Cells and in Prostate Tumors of PTEN−/− Transgenic Mice
In this study, scientists have taken advantage of over-expression of eukaryotic translation initiation factor 4E in prostate cancer cells to design a viral-based targeting system of prostate cancer. [Cancer Gene Ther] Abstract
ErbB2/Her-2 Regulates the Expression of Akt2 in Prostate Cancer Cells
In this study, the regulation of Akt2 expression in LNCaP, DU145, and PC-3 prostate cancer cell lines was investigated. [Prostate] Abstract
XMRV Accelerates Cellular Proliferation, Transformational Activity, and Invasiveness of Prostate Cancer Cells by Downregulating p27Kip1
Researchers demonstrate that xenotropic murine leukemia virus-related retrovirus (XMRV) infection can accelerate cellular proliferation, enhance transformation, and increase invasiveness of slow growing prostate cancer cells. [Prostate] Abstract
CLINICAL RESEARCH
Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
The activity of the novel antitumor agent tasquinimod with S100A9 as a molecular target was investigated in men with metastatic castration-resistant prostate cancer and minimal symptoms. [J Clin Oncol] Abstract
HER2 Overcomes PTEN (Loss)-Induced Senescence to Cause Aggressive Prostate Cancer
In this study, scientists show that patients who develop prostate tumors with low levels of PTEN and high levels of HER2/3 have a poor prognosis. [Proc Natl Acad Sci U S A] Abstract
GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy
A phase I clinical trial was conducted to evaluate the safety and activity of the neoadjuvant intraprostatic injection of GLIPR1 expressing adenovirus for high-risk localized prostate cancer before radical prostatectomy. [Clin Cancer Res] Abstract
Multicenter Phase II Study of Trabectedin in Patients with Metastatic Castration-Resistant Prostate Cancer
This multicenter phase II trial evaluated the efficacy and safety of trabectedin in metastatic castration-resistant prostate cancer. [Ann Oncol] Abstract

|
|
|
|